1228035-41-3

Upstream product

• 123-75-1 pyrrolidine 
• 1147271-26-8 2-amino-8-(bromomethyl)-4-phenyl-5H-indeno[1,2-d]-pyrimidin-5-one 
• 1228035-27-5 2-(bis(methylthio)methylene)-6-methyl-2,3-dihydro-1H-inden-1-one 
• 1228035-28-6 2-amino-8-methyl-4-(methylthio)-5H-indeno[1,2-d]pyrimidin-5-one 
• 1228035-29-7 C₂₃H₂₇N₃O₅S 
• 1147077-82-4 2-amino-8-methyl-4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one 
• 24623-20-9 2,3-dihydro-6-methyl-1H-inden-1-one 
• 60031-11-0 2-benzylidene-6-methylindan-1-one 
• 100-52-7 benzaldehyde 
• 1147077-77-7 C₂₈H₂₉N₃O₅ 

Relevant academic research and scientific papers

ARYLINDENOPYRIMIDINES FOR TREATING NEURODEGENERATIVE AND MOVEMENT DISORDERS WHILE MINIMIZING CARDIAC TOXICITY

This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic

ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING

This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic

In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease

The in vivo characterization of a dual adenosine A2A/A 1 receptor antagonist in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimizat